Medicine & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AlphaVax
AlphaVax reports AIDS vaccine induced antibody response to HIV gag antigen in 100% of recipients
October 13th, 2006
AlphaVax, a North Carolina-based vaccine company, presented an analysis of blinded results recently at the AIDS Vaccine 2006 meeting in Amsterdam from a phase I clinical trial, run in collaboration with the Division of AIDS (DAIDS) at the National Institutes of Health (NIH) and the HIV Vaccine Trials Network (HVTN), evaluating a prototype HIV vaccine incorporating the HIV gag gene made using the company's alphavaccine technology. Preliminary analysis of the blinded data, making an assumption that the placebo recipients generated no immune response, suggests that the vaccine induced an antibody response to the HIV gag antigen in 100% of the recipients at the highest dose...
Source: Medicine & Law Weekly (2006-10-13)
|
